Cerus Corporation
NASDAQ:CERSMedical - Devices
Healthcare
$1.90 +2.92%
+$0.08 today
- Market cap
- $383.71M
- Beta
- 1.77
- P/E (TTM)
- -53.8
- EPS (TTM)
- -$0.05
52W Low $1.15High $3.15
Volume 6.69M
Average 2.33M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$11.36M
FY 2025 · Annual
+0.0% YoYInvesting Cash Flow
-$8.13M
FY 2025 · Annual
Financing Cash Flow
$4.96M
FY 2025 · Annual
+0.0% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (54.38M) | (42.83M) | (37.49M) | (20.96M) | (15.63M) |
| Depreciation & Amortization | 3.15M | 2.98M | 2.6M | 1.86M | 1.86M |
| Deferred Income Tax | 462K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 23.57M | 24.46M | 20.27M | 22.87M | 22.87M |
| Change in Working Capital | (9.4M) | (16.05M) | (32.04M) | 5.23M | (6.83M) |
| Accounts Receivables | (4.22M) | (9.2M) | (1.1M) | 5.5M | (396K) |
| Inventory | (19.61M) | (1.77M) | (14.95M) | 7.03M | (14.68M) |
| Accounts Payables | 12.2M | (4.91M) | (7.34M) | (1.48M) | 5.73M |
| Other Working Capital | 2.22M | (179K) | (8.65M) | (5.83M) | 2.52M |
| Other Non-Cash Items | 2.67M | 5.82M | 3.49M | 2.37M | 9.09M |
| Operating Cash Flow | (33.92M) | (25.62M) | (43.17M) | 11.36M | 11.36M |
| Capital Expenditures | (910K) | (2M) | (4.6M) | (2.84M) | (2.84M) |
| Acquisitions (Net) | 910K | (10.46M) | 0 | 0 | 0 |
| Purchases of Investments | (52.07M) | (29.64M) | (2.49M) | (42.98M) | (42.98M) |
| Sales of Investments | 65.66M | 40.1M | 15.71M | 37.68M | 37.68M |
| Other Investing Activities | (910K) | 10.46M | 0 | 0 | 0 |
| Investing Cash Flow | 12.69M | 8.46M | 8.62M | (8.13M) | (8.13M) |
| Debt Repayment | 21.18M | 212K | 9.92M | 4.3M | (329K) |
| Common Stock Issued | 2.74M | 0 | 0 | 0 | 560K |
| Common Stock Repurchased | 0 | (104K) | (175K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 10.37M | 4.08M | 925K | 667K | 4.73M |
| Financing Cash Flow | 34.29M | 4.19M | 10.67M | 4.96M | 4.96M |
| Effect of Forex Changes | (919K) | (727K) | (128K) | (191K) | (191K) |
| Net Change in Cash | 12.14M | (13.69M) | (24M) | 8M | 8M |
| Free Cash Flow | (34.83M) | (27.62M) | (47.77M) | 8.52M | 8.52M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$15.6M
+ D&A$1.9M
+ Stock-Based Comp$22.9M
+ Deferred Tax$0
- Working Capital-$6.8M
+ Other Non-Cash$9.1M
= Operating Cash Flow$11.4M
- Capex-$2.8M
= Free Cash Flow$8.5M
Analysis
FY2025 free cash flow is $8.5M. FCF conversion is -54.5% of net income. Operating cash flow was $11.4M, with capex of -$2.8M. The largest bridge item is Stock-Based Comp at $22.9M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| S-3 | S-3 filing | Nov 2, 2026 | |
| 8-K | Current report | Nov 2, 2026 | |
| 10-Q | Quarterly report | Nov 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 17, 2026 |
Does CERS generate free cash flow?
Cerus Corporation (CERS) generated $8.52M of free cash flow in fiscal 2025.
How much operating cash flow does CERS produce?
Operating cash flow was $11.36M, before capital expenditures of $2.84M.
Continue the stock analysis
Jump to another research area for this company.